BACKGROUND:Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [PORT] class II-IV) were randomized 1:1 to receive either intravenous-to-oral solithromycin or moxifloxacin for 7 once-daily doses. All patients received 400 mg intravenously on day 1 and were permitted to switch to oral dosing when clinically indicated. The primary objective was to demonstrate noninferiority (10% margin) of solithromycin to moxifloxacin in achievement of early clinical response (ECR) assessed 3 days after first dose in the intent-to-treat (ITT) population. Secondary endpoints included demonstrating noninferiority in ECR in the microbiological ITT population (micro-ITT) and determination of investigator-assessed success rates at the short-term follow-up (SFU) visit 5-10 days posttherapy. RESULTS: In the ITT population, 79.3% of solithromycin patients and 79.7% of moxifloxacin patients achieved ECR (treatment difference, -0.46; 95% confidence interval [CI], -6.1 to 5.2). In the micro-ITT population, 80.3% of solithromycin patients and 79.1% of moxifloxacin patients achieved ECR (treatment difference, 1.26; 95% CI, -8.1 to 10.6). In the ITT population, 84.6% of solithromycin patients and 88.6% of moxifloxacin patients achieved clinical success at SFU based on investigator assessment. Mostly mild/moderate infusion events led to higher incidence of adverse events overall in the solithromycin group. Other adverse events were comparable between treatment groups. CONCLUSIONS:Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin. Solithromycin has potential to provide an intravenous and oral option for monotherapy for community-acquired bacterial pneumonia. CLINICAL TRIALS REGISTRATION: NCT01968733.
RCT Entities:
BACKGROUND:Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [PORT] class II-IV) were randomized 1:1 to receive either intravenous-to-oral solithromycin or moxifloxacin for 7 once-daily doses. All patients received 400 mg intravenously on day 1 and were permitted to switch to oral dosing when clinically indicated. The primary objective was to demonstrate noninferiority (10% margin) of solithromycin to moxifloxacin in achievement of early clinical response (ECR) assessed 3 days after first dose in the intent-to-treat (ITT) population. Secondary endpoints included demonstrating noninferiority in ECR in the microbiological ITT population (micro-ITT) and determination of investigator-assessed success rates at the short-term follow-up (SFU) visit 5-10 days posttherapy. RESULTS: In the ITT population, 79.3% of solithromycinpatients and 79.7% of moxifloxacinpatients achieved ECR (treatment difference, -0.46; 95% confidence interval [CI], -6.1 to 5.2). In the micro-ITT population, 80.3% of solithromycinpatients and 79.1% of moxifloxacinpatients achieved ECR (treatment difference, 1.26; 95% CI, -8.1 to 10.6). In the ITT population, 84.6% of solithromycinpatients and 88.6% of moxifloxacinpatients achieved clinical success at SFU based on investigator assessment. Mostly mild/moderate infusion events led to higher incidence of adverse events overall in the solithromycin group. Other adverse events were comparable between treatment groups. CONCLUSIONS: Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin. Solithromycin has potential to provide an intravenous and oral option for monotherapy for community-acquired bacterial pneumonia. CLINICAL TRIALS REGISTRATION: NCT01968733.
Authors: Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: George G Zhanel; Erika Hartel; Heather Adam; Sheryl Zelenitsky; Michael A Zhanel; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew J Walkty; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky Journal: Drugs Date: 2016-12 Impact factor: 9.546
Authors: Christopher MacLauchlin; Stephen E Schneider; Kara Keedy; Prabhavathi Fernandes; Brian D Jamieson Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Jason E Lang; Christoph P Hornik; Carrie Elliott; Adam Silverstein; Chi Hornik; Amira Al-Uzri; Miroslava Bosheva; John S Bradley; Charissa Fay Corazon Borja-Tabora; David Di John; Ana Mendez Echevarria; Jessica E Ericson; David Friedel; Ferenc Gonczi; Marie Grace Dawn Isidro; Laura P James; Krisztina Kalocsai; Ioannis Koutroulis; Istvan Laki; Anna Lisa T Ong-Lim; Marta Nad; Gabor Simon; Salma Syed; Eva Szabo; Daniel K Benjamin; Michael Cohen-Wolkowiez Journal: Pediatr Infect Dis J Date: 2022-06-07 Impact factor: 3.806
Authors: Daniel Gonzalez; Laura P James; Amira Al-Uzri; Miroslava Bosheva; Felice C Adler-Shohet; Susan R Mendley; John S Bradley; Claudia Espinosa; Eva Tsonkova; Kathryn Moffett; Lucila Marquez; Kari A Simonsen; Stefan Stoilov; Felix Boakye-Agyeman; Theresa Jasion; Christoph P Hornik; Robert Hernandez; Daniel K Benjamin; Michael Cohen-Wolkowiez Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: Ryan J Beechinor; Michael Cohen-Wolkowiez; Theresa Jasion; Christoph P Hornik; Jason E Lang; Robert Hernandez; Daniel Gonzalez Journal: Ther Drug Monit Date: 2019-12 Impact factor: 3.118
Authors: Sara N Salerno; Andrea Edginton; Michael Cohen-Wolkowiez; Christoph P Hornik; Kevin M Watt; Brian D Jamieson; Daniel Gonzalez Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-10-25